METHOD: We carry out an observational study where reviewed the PET/CT studies with PSMA marked with Fluor-18 ( 18 F) carried out from February 2019 to September 2020. We analyzed the average value of hepatic uptake SUV lean average (SUVlave), acquisition time, age, reason from the study, focal, multifocal and diffuse prostate uptake, analysis of the location of metastases, level of prostate specific antigen (PSA), we describe uptakes of non-prostate origin and focal uptakes in ribs without anatomical representation. RESULTS: The average hepatic SUVlave was 9.7, the acquisition times were variable (52 - 183 minutes) without alterations in the white-background relationship, the most frequent indication for the study was staging, the uptake in ribs without anatomical representation were considered benign with certain characteristics, PET/CT has the ability to detect neoplastic activity with low PSA levels in lymph nodes < 5 mm and bone metastatic status. CONCLUSION: PET/CT with 18 F-PSMA has advantages over bone scan and computed tomography of the abdomen and pelvis for the staging of prostate cancer.
Lozano Jose Antonio De, F. (2004) Prostate Cancer. Editorial OFFARM, 23, 84.
Aldaco-Sarvide, F., Pérez-Pérez, P., Cervantes-Sánchez, G., Torrecillas-Torres, L., Erazo-Valle-Solís, A.A., Cárdenas-Cárdenas, R.E., et al. (2018) Mortality from Cancer in Mexico: 2015 Update. Gaceta Mexicana de Oncología, 17, 24-30. https://doi.org/10.24875/j.gamo.M18000105
Botelho, T.R. (2005) Revitalização de centros urbanos no Brasil: uma análise comparativa das experiências de Vitória, Fortaleza e São Luís. EURE (Santiago), 31, 53-71. https://doi.org/10.4067/S0250-71612005009300004
Fendler, W.P., Schmidt, D.F., Wenter, V., Thierfelder, K.M., Zach, C., Stief, C., et al. (2016) 68 Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of Nuclear Medicine, 57, 1720-1725. https://doi.org/10.2967/jnumed.116.172627
Schillaci, O., Calabria, F., Tavolozza, M., Cicciò, C., Carlani, M., Caracciolo, C.R., et al. (2010) 18 F-Choline PET/CT Physiological Distribution and Pitfalls in Image Interpretation: Experience in 80 Patients with Prostate Cancer. Nuclear Medicine Communications, 31, 39-45. https://doi.org/10.1097/MNM.0b013e328330adc5
García Vicente, A.M., Núñez García, A., Soriano Castrejón, A.M., Jiménez Londoño, G.A., Cordero García, J.M. and Palomar Muñoz, A. (2013) Falsos Positivos en PET-TC con 18 F-Colina en pacientes con cáncer de próstata. Revista Española de Medicina Nuclear e Imagen Molecular, 32, 37-39.
Hofman, M.S., Hicks, R.J., Maurer, T. and Eiber, M. (2018) Prostate-Specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. RadioGraphics, 38, 200-217. https://doi.org/10.1148/rg.2018170108
Carrilho Vaz, S., Silva, Â., Oliveira, C., Marques, R., Galzerano, A. and Castillo-Martin, M. (2020) Impact of PSMA PET/CT in Prostate Cancer Patient’s Clinical Management: A Pictorial Essay of Interesting Cases with Histologic Confirmation. Clinical and Translational Imaging, 8, 207-226. https://doi.org/10.1007/s40336-020-00372-2
Afshar-Oromieh, A., Haberkorn, U., Eder, M., Eisenhut, M. and Zechmann, C.M. (2012) [ 68 Ga]Gallium-Labelled PSMA Ligand as Superior PET Tracer for the Diagnosis of Prostate Cancer: Comparison with 18 F-FECH. European Journal of Nuclear Medicine and Molecular Imaging, 39, 1085-1086. https://doi.org/10.1007/s00259-012-2069-0
Demirci, E., Sahin, O.E., Ocak, M., Akovali, B., Nematyazar, J. and Kabasakal, L. (2016) Normal Distribution Pattern and Physiological Variants of 68 Ga-PSMA-11 PET/CT Imaging. Nuclear Medicine Communications, 37, 1169-1179. https://doi.org/10.1097/MNM.0000000000000566
Giesel, F.L., Hadaschik, B., Cardinale, J., Radtke, J., Vinsensia, M., Lehnert, W., et al. (2017) F-18 Labelled PSMA-1007: Biodistribution, Radiation Dosimetry and Histopathological Validation of Tumor Lesions in Prostate Cancer Patients. European Journal of Nuclear Medicine and Molecular Imaging, 44, 678-688. http://dx.doi.org/10.1007/s00259-016-3573-4
Maurer, T., Gschwend, J.E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., et al. (2016) Diagnostic efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology, 195, 1436-1443. https://doi.org/10.1016/j.juro.2015.12.025
Luis, C., Eduardo, T.J., Francisco, C., Adriana, N.J., Adriana, N.J. and Hernán, L. (2018) Application of Positron Emission Tomography in Prostate Cancer Marked with 68 Ga-PSMA: Revision and Actuality.
Uprimny, C., Kroiss, A.S., Decristoforo, C., Fritz, J., von Guggenberg, E., Kendler, D., et al. (2017) 68 Ga-PSMA-11 PET/CT in Primary Staging of Prostate Cancer: PSA and Gleason Score Predict the Intensity of Tracer Accumulation in the Primary Tumour. European Journal of Nuclear Medicine and Molecular Imaging, 44, 941-949. https://doi.org/10.1007/s00259-017-3631-6
Mottet, N., Bastian, P.J., Bellmunt, J., van den Bergh, R.C.N., Bolla, M., van Casteren, N.J., et al. (2014) Guidelines on Prostate Cancer—Booklet. European Urology, 65, 124-137.
Janssen, J.C., Meißner, S., Woythal, N., Prasad, V., Brenner, W., Diederichs, G., et al. (2018) Comparison of Hybrid 68 Ga-PSMA-PET/CT and Tc-DPD-SPECT/CT for the Detection of Bone Metastases in Prostate Cancer Patients: Additional Value of Morphologic Information from Low Dose CT. European Radiology, 28, 610-619. https://doi.org/10.1007/s00330-017-4994-6
Carlin, B.I. and Andriole, G.L. (2000) The Natural History, Skeletal Complications, and Management of Bone Metastases in Patients with Prostate Carcinoma. Cancer, 88, 2989-2994. https://doi.org/10.1002/1097-0142(20000615)88:12+%3C2989::AID-CNCR14%3E3.0.CO;2-Q
Pyka, T., Weirich, G., Einspieler, I., Maurer, T., Theisen, J., Hatzichristodoulou, G., et al. (2016) 68 Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. Journal of Nuclear Medicine, 57, 367-371. https://doi.org/10.2967/jnumed.115.164442
Singhal, A., Chandra, B. and Seth, S. (2019) Pictorial Essay Nonspecific Uptake of 68 Ga-Prostate-Specific Membrane Antigenin Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of LiteratureAbstract. Indian Journal of Nuclear Medicine, 33, 359-362.
Backhaus, P., Noto, B., Avramovic, N., Grubert, L.S., Huss, S., Bögemann, M., Stegger, L., et al. (2018) Targeting PSMA by Radioligands in Non-Prostate Disease—Current Status and Future Perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 45, 860-877. https://doi.org/10.1007/s00259-017-3922-y
Chang, S.S., O’Keefe, D.S., Bacich, D.J., Reuter, V.E., Heston, W.D. and Gaudin, P.B. (1999) Prostate-Specific Membrane Antigen Is Produced in Tumor-Associated Neovasculature. Clinical Cancer Research, 5, 2674-2681.
Sepúlveda, L., Gorgal, T., Pires, V. and Rodrigues, F. (2015) Prostate Cancer Metastatic to the Cervical Lymph Nodes. Case Reports in Urology, 2015, Article ID: 263978. https://doi.org/10.1155/2015/263978
Damjanovic, J., Janssen, J.-C., Prasad, V., Diederichs, G., Walter, T., Brenner, W., et al. (2019) 68 Ga-PSMA-PET/CT for the Evaluation of Liver Metastases in Patients with Prostate Cancer. Cancer Imaging, 19, Article No. 37. https://doi.org/10.1186/s40644-019-0220-x
Bubendorf, L., Schöpfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., et al. (2000) Metastatic Patterns of Prostate Cancer: An Autopsy Study of 1,589 Patients. Human Pathology, 31, 578-583.
Chen, M.Y., Franklin, A., Yaxley, J., Gianduzzo, T., McBean, R., Wong, D., et al. (2020) Solitary Rib Lesions Showing Prostate-Specific Membrane Antigen (PSMA) Uptake in Pre-Treatment Staging 68 Ga-PSMA-11 Positron Emission Tomography Scans for Men with Prostate Cancer: Benign or Malignant? BJU International, 126, 396-401. https://doi.org/10.1111/bju.15152
Pouessel, D., Gallet, B., Bibeau, F., Avancès, C., Iborra, F., Sénesse, P., et al. (2007) Liver Metastases in Prostate Carcinoma: Clinical Characteristics and Outcome. BJU International, 99, 807-811. https://doi.org/10.1111/j.1464-410X.2006.06663.x